Literature DB >> 3515942

IgA nephropathy in children: significance of glomerular basement membrane deposition of IgA.

S P Andreoli, M N Yum, J M Bergstein.   

Abstract

Seventeen children with IgA nephropathy were grouped according to the absence (group I, n = 10) or presence (group II, n = 7) of glomerular basement membrane (GBM) deposition of IgA to determine whether GBM deposition of IgA correlated with laboratory or pathologic data at diagnosis or clinical status at follow-up. Children in group II had significantly (p less than 0.01) more proteinuria at diagnosis than children in group I. The percentage of glomeruli demonstrating crescent formation was significantly (p less than 0.05) higher in group II biopsies. Chronic changes of fibrous crescents, segmental sclerosis, global obsolescence, tubular atrophy, and interstitial fibrosis were also significantly (p less than 0.001) more common in group II biopsies. After a mean follow-up period of 2 years, all children in group II have persistent proteinuria of more than 1 g/24 h, and 3 of 5 have renal insufficiency (2 require dialysis). In contrast, 2 of 9 group I children have proteinuria exceeding 1 g/24 h, and only 1 has renal insufficiency. We conclude that, as compared to children with IgA localized to the mesangium, children with IgA nephropathy and GBM deposition of IgA have a higher urinary protein excretion at the time of diagnosis, more severe histologic alterations including a greater percentage of glomeruli demonstrating crescent formation, more chronic changes of segmental or global sclerosis, tubular atrophy, and interstitial fibrosis. Such children usually have persistent proteinuria and are more likely to develop progressive renal disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3515942     DOI: 10.1159/000167049

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  14 in total

1.  Urinary neopterin: an immune activation marker in mesangial proliferative glomerulonephritis.

Authors:  Kazuyuki Ueno; Masaki Shimizu; Tadafumi Yokoyama; Sayaka Ishikawa; Yuko Tasaki; Natsumi Inoue; Naotoshi Sugimoto; Kazuhide Ohta; Akihiro Yachie
Journal:  Clin Exp Nephrol       Date:  2014-05-25       Impact factor: 2.801

Review 2.  Pathology of IgA nephropathy.

Authors:  Ian S D Roberts
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

3.  Treatment of IgA nephropathy in children.

Authors:  U S Alon
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

Review 4.  Experimental IgA nephropathy: factors influencing IgA-immune complex deposition in the glomerulus.

Authors:  A Chen; C H Wei; W H Lee; C Y Lin
Journal:  Springer Semin Immunopathol       Date:  1994

Review 5.  IgA nephropathy in children and adults.

Authors:  N Yoshikawa; H Nakamura; H Ito
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Treatment of severe IgA nephropathy in children.

Authors:  S P Andreoli; J M Bergstein
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

7.  Asymptomatic haematuria and proteinuria: renal pathology and clinical outcome in 54 children.

Authors:  S Hisano; K Ueda
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

8.  Prognostication in children with renal disease--with emphasis on IgA nephropathy.

Authors:  R J Hogg; R Browne
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

9.  Prognostic indicators in children with IgA nephropathy--report of the Southwest Pediatric Nephrology Study Group.

Authors:  R J Hogg; F G Silva; R J Wyatt; J S Reisch; J C Argyle; D A Savino
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

10.  Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy.

Authors:  Anthony S Alvarado; Nicole K Andeen; Sergey Brodsky; Alice Hinton; Tibor Nadasdy; Charles E Alpers; Christopher Blosser; Behzad Najafian; Brad H Rovin
Journal:  Nephrol Dial Transplant       Date:  2018-07-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.